Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

@article{Iskedjian2007MetaanalysisOC,
  title={Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain},
  author={Michael Iskedjian and Basil G Bereza and Allan S. Gordon and Charles Piwko and Thomas R Einarson},
  journal={Current Medical Research and Opinion},
  year={2007},
  volume={23},
  pages={17 - 24}
}
ABSTRACT Objective: Debilitating pain, occurring in 50–70% of multiple sclerosis (MS) patients, is poorly understood and infrequently studied. We summarized efficacy and safety data of cannabinoid-based drugs for neuropathic pain. Data sources: Studies were identified from Medline, Embase, and Cochrane databases; Bayer Healthcare provided additional trials. Study selection: Accepted were randomized, double-blinded placebo-controlled trials of cannabinoid-based treatments for MS-related… Expand
Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis
TLDR
Well-designed, large, randomized studies are required to better evaluate specific dosage, duration of intervention, and the effect of this intervention on physical and psychologic function in patients with chronic NP. Expand
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
TLDR
There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity and low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Expand
Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
TLDR
A systematic review and meta-analysis of all randomized controlled trials of Cannabis-based medicines suggests that CBMs might be effective for chronic pain treatment, based on limited evidence, primarily for neuropathic pain patients. Expand
Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression
TLDR
Efficacy for neuropathic and non-neuropathic pain was similar, and pain intensity of chronic non-cancer patients was reduced by cannabinoids consumption, but effect sizes were small. Expand
Systematic review and meta-analysis of cannabis treatment for chronic pain.
TLDR
Systematic review and meta-analysis of double-blind randomized controlled trials that compared any cannabis preparation to placebo among subjects with chronic pain suggests that cannabis treatment is moderately efficacious for treatment of chronic pain, but beneficial effects may be partially (or completely) offset by potentially serious harms. Expand
The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review.
TLDR
Cannabis-based medicinal extracts used in different populations of chronic nonmalignant neuropathic pain patients may provide effective analgesia in conditions that are refractory to other treatments. Expand
Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data.
TLDR
This novel Bayesian meta-analysis of individual patient data from 5 randomized trials suggests that inhaled cannabis may provide short-term relief for 1 in 5 to 6 patients with neuropathic pain. Expand
Nabiximols in chronic neuropathic pain: a meta-analysis of randomized placebo-controlled trials.
TLDR
Nabiximols was superior to placebo for reduction of chronic neuropathic pain, with a small effect size, in larger RCTs designed to assess the effect of nabiximol in neuropathicPain. Expand
Efficacy and safety of medical cannabinoids in older subjects: A systematic review
TLDR
Two studies showed that THC might be useful in treatment of anorexia and behavioral symptoms in dementia, and adverse events were more common during cannabinoid treatment compared to the control treatment, and were most frequently sedation like symptoms. Expand
Tetrahydrocannabinol in the treatment of neuropsychiatric symptoms in dementia
TLDR
Two studies showed that THC might be useful in treatment of anorexia and behavioral symptoms in dementia, and adverse events were more common during cannabinoid treatment compared to the control treatment, and were most frequently sedation like symptoms. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
TLDR
Treatment with cannabinoids did not have a beneficial effect on spasticity when assessed with the Ashworth scale, but objective improvement in mobility and patients' opinion of an improvement in pain suggest cannabinoids might be clinically useful. Expand
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
TLDR
These data provide limited evidence for a longer term treatment effect of cannabinoids in multiple sclerosis, and a long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS. Expand
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
TLDR
Dronabinol has a modest but clinically relevantanalgesic effect on central pain in patients with multiple sclerosis and on the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active treatment compared with placebo. Expand
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
TLDR
CBM was generally well tolerated, although more patients on CBM than placebo reported dizziness, dry mouth, and somnolence, and Cognitive side effects were limited to long-term memory storage. Expand
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial
TLDR
The study medications were generally well tolerated with the majority of adverse events, including intoxication type reactions, being mild to moderate in severity and resolving spontaneously. Expand
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.
TLDR
In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo and no major adverse effects were observed. Expand
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
TLDR
Spasticity VAS scores were significantly reduced by CBME (Sativex) in comparison with placebo (P- 0.001), there were no significant adverse effects on cognition or mood and intoxication was generally mild. Expand
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms
TLDR
Cannabis medicinal extracts can improve neurogenic symptoms unresponsive to standard treatments, and unwanted effects are predictable and generally well tolerated. Expand
Delta‐9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief
TLDR
The unaffected electrically induced axon reflex flare, but decreased pain perception, suggests a central mode of action of the cannabinoid, and demonstrates that a generalized statement that delta‐9-THC is an analgetic drug cannot be made. Expand
Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ‘N of 1’ studies
TLDR
A total of 34 ‘N of 1’ studies were undertaken using this novel therapy for patients with chronic, mainly neuropathic, pain and associated symptoms to explore efficacy, tolerability, safety and dosages of CBME. Expand
...
1
2
3
4
5
...